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Snake envenoming is a highly relevant public health issue that
causes substantial morbidity and mortality in tropical regions
(more than 138,000 deaths every year)1, but remains largely
neglected by funding bodies, public health authorities, the phar-
maceutical industry and health advocacy groups2. The true burden
of snakebite remains unknown, although it has been estimated to
be as high as 1,841,000 envenomings annually3. However, since
many tropical snakebite victims first seek traditional treatment
rather than presenting at a healthcare facility, this number may be
an underestimate, as it is known that many snakebite victims die at
home and those deaths remain unrecorded2,4. Specific antivenom
therapies, which consist of immunoglobulins purified from serum
or plasma of animals following hyperimmunization by selected
venom(s), represent life-threatening treatments of snake enve-
noming5. They are given intravenously in a clinical environment
and can neutralise the coagulopathic, haemorrhagic and hypo-
tensive actions of snake venoms, among other signs of systemic
envenoming6. However, antivenoms are highly specific in neu-
tralising only one or several venoms from species of a certain
geographical location7,8, due to extensive variation in venom
composition among different snake species9. In addition,
antivenom-associated adverse reactions are common10, with both
acute reactions (anaphylactic shock or immediate hypersensitiv-
ity) and delayed reactions (treatment-induced serum sickness)
reported11. Finally, antivenoms are often limited in terms of their
availability and/or poorly distributed, and are typically unafford-
able to those who live in impoverished rural regions of the
tropicsdi.e., those who are at the greatest risk of snakebite12.
A promising approach for solving the critical therapeutic gap
between a snakebite occurring and delayed presentation to a
hospital setting, is the use of small molecule toxin inhibitors that
can be administered orally and are able to (at least partially)
neutralise enzymatic snake venom toxicities13e17. The venoms of
many snakes, particularly those of vipers (Viperinae and Crotali-
nae; both family Viperidae) cause coagulopathic and haemor-
rhagic toxicities by the combined actions of different toxin
isoforms of enzymatic families, such as phospholipase A2s
(PLA2s), snake venom serine proteases (SVSPs), and snake venom
metalloproteinases (SVMPs)6,7. Snake venom hydrolytic enzymes
are associated with a number of systemic clinical syndromes, of
which coagulopathy is one of the most important in terms of
contribution towards mortality5,6. PLA2s can hydrolyse glycer-
ophospholipids and hence degrade membranes, or damage
sarcolemma by hydrophobic interactions18. SVSPs cant al., Neutralising effects of small mo
ttps://doi.org/10.1016/j.apsb.2020.09proteolytically degrade fibrinogen and regulate factor V and
plasminogen to perturb haemostasis19,20. SVMPs can activate
prothrombin and/or factor X, hydrolyse and degrade endothelial
cell basement membranes, and preclude muscle fibre regeneration,
all of which may contribute to perturbations of blood coagulation
and induce severe haemorrhaging21. These enzymes can poten-
tially be inhibited by small molecule toxin inhibitors, such as the
PLA2 inhibitor varespladib
22e24 and the metalloproteinase inhib-
itor marimastat17,25,26. Varespladib, which is a nonspecific PLA2
inhibitor and was a drug candidate for treating atherosclerotic
lesions27, coronary heart disease28,29, and acute chest syndrome
induced by sickle cell disease23, has been the focus of consider-
able recent research as a potential therapeutic candidate for
snakebite treatment13,14,22,24. Varespladib has showed efficient
inhibition of venom-induced PLA2 activity
13,22 and has been
demonstrated to reduce haemorrhage, myotoxicity and neurotox-
icity in murine models after snake envenomation13,24, as well as
protect against venom-induced lethality caused by certain snake
species and, thus, is now considered as a potential pre-referral
drug candidate for treating snakebite22.
Similarly, other small molecule inhibitor-based antidote can-
didates have been studied for their potential to inhibit SVMP and
SVSP toxin families, and therefore serve as alternative (or
adjunct), non-antibody based, future treatments for snakebite7,30.
One such molecule is marimastat, which is a water-soluble broad
spectrum matrix metalloprotease inhibitor31,32, and which binds to
the active site of matrix metalloproteinases to form non-covalent
complexes17,33. Hence it is considered as a potential inhibitor of
SVMPs which share regions of structural similarity to matrix
metalloproteinases26,34,35. Marimastat has been evaluated for in-
hibition of angiogenesis36 and the spread and growth of can-
cers25,32. Because SVMP toxins are major constituents of many
snake venoms, marimastat was repurposed as a candidate to treat
snake envenomation and has since been shown to effectively
inhibit the metalloprotease activity of snake venoms in vitro and
neutralise systemic toxicity and lethality in vivo in mice enve-
nomed with viper venoms17,37.
SVMPs are Zn2þ-dependent proteinases, which become inac-
tive after Zn2þ removal from their active site38. Many metal
chelator treatments have been proven to be safe in humans and are
used as marketed drugs for chelating heavy metals after heavy
metal poisoning39,40. A small number of these drugs have been
shown to be effective in neutralising the venom-induced proteo-
lytic, myotoxic, haemorrhagic and coagulation activities in murine
snakebite models26,41. Dimercaprol, which was developed during
World War II by British biochemists42 and is listed by the Worldlecule toxin inhibitors on nanofractionated coagulopathic Crotalinae snake
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is a widely used antidote in treating heavy metal poisoning44,45,
and is recommended for treating Wilson’s disease46. A recent
study from Albulescu et al.16 showed that dimercaprol could
effectively inhibit SVMP activity, counteract coagulopathic effects
and neutralise lethal effects of envenoming caused by certain
snake species (Viperinae: Echis) in murine models.
In this study we used a combination of nanofractionation an-
alytics and high-throughput coagulation assaying to investigate
the potential of varespladib, marimastat and dimercaprol as drug
repurposing candidates for new, non-antibody-based, snakebite
treatments against coagulopathic pit viper (Crotalinae) snake
venoms. The coagulation activities of separated toxins from the
venoms of the medically important pit vipers Bothrops asper,
Bothrops jararaca, Calloselasma rhodostoma and Dein-
agkistrodon acutus were evaluated in the presence of the various
drug repurposing candidates by using a high-throughput screening
(HTS) coagulation assay after nanofractionation by liquid chro-
matography (LC) with parallel mass spectrometry (MS). We then
identified the coagulopathic toxins, including those that were
neutralised by the various small molecule toxin inhibitors, by
correlating the resulting bioactivity chromatograms to the parallel
obtained MS and proteomics data. Our results show that vares-
pladib, marimastat and/or dimercaprol exhibit different specific-
ities and potencies against coagulopathic venom toxins, but that
all show promise as novel therapeutics for treating coagulopathic
snakebites.2. Materials and methods2.1. Chemical and biological reagents
Deionized water was purified by a Milli-Q Plus system (Millipore,
Amsterdam, The Netherlands). Acetonitrile (ACN) and formic
acid (FA) (Biosolve, Valkenswaard, The Netherlands) were used
for the HPLC analyses. Calcium chloride (CaCl2 dihydrate;
SigmaeAldrich, Zwijndrecht, The Netherlands) was used to de-
citrate plasma to initiate coagulation in the coagulation assay.
Phosphate buffered saline (PBS) buffer was prepared by dissolv-
ing PBS tablets (SigmaeAldrich) in Milli-Q according to the
manufacturer’s instructions, before storage at 4 C until use, but
for no longer than one week prior to use. Bovine plasma was
purchased from Biowest (Nuaille´, France; sodium citrated, sterile
filtered, 500 mL per bottle), and prior to use was defrosted in a
warm water bath and then quickly transferred to 15 mL Cen-
triStar™ tubes (Corning Science, Reynosa, Mexico) once fully
defrosted. The 15 mL tubes were then re-frozen immediately and
stored at 80 C until use. Varespladib, marimastat and dimer-
caprol (SigmaeAldrich) were dissolved in DMSO (99.9%,
SigmaeAldrich) to a concentration of 10 mmol/L and stored at
20 C. Prior to use, they were diluted in PBS buffer to the
concentrations used for testing. Lyophilized venoms from B. asper
(Costa Rica “Atlantic”), B. jararaca (Brazil), C. rhodostoma
(captive bred, Thailand ancestry) and D. acutus (captive bred,
Chinese ancestry) were provided by the Centre for Snakebite
Research and Interventions, Liverpool School of Tropical Medi-
cine (UK). This facility and its protocols for the expert husbandry
of snakes are approved and inspected by the UK Home Office and
the Liverpool School of Tropical Medicine and University of
Liverpool Animal Welfare and Ethical Review Boards. ThePlease cite this article as: Xie Chunfang et al., Neutralising effects of small mo
venoms, Acta Pharmaceutica Sinica B, https://doi.org/10.1016/j.apsb.2020.09lyophilized venoms were dissolved in water at 5.0  0.1 mg/mL
concentrations, and stored at 80 C until use.
2.2. LC‒MS with parallel nanofractionation
A UPLC system (‘s Hertogenbosch, The Netherlands), which was
controlled by a Shimadzu Lab Solutions software by the help of a
Shimadzu CBM-20A System Controller, was used for venom
separation. For each analysis, 50 mL venom solution (1.0 mg/mL)
was injected by a Shimadzu SIL-30AC autosampler after diluting
the stock venom solutions (5.0  0.1 mg/mL) in Milli-Q. The
gradient separation was performed on a Waters XBridge reversed-
phase C18 column (250 mm  4.6 mm column with 3.5 mm pore-
size). The temperature of the column was controlled at 30 C by a
Shimadzu CTO-30A column oven. The total solvent flow rate was
0.5 mL/min and was controlled by two Shimadzu LC-30AD
pumps. The mobile phases consisted of eluent A (98% H2O, 2%
ACN, and 0.1% FA) and eluent B (98% ACN, 2% H2O, and 0.1%
FA). The mobile phase gradients were run as follows: a linear
increase of eluent B from 0 to 50% in 20 min followed by a linear
increase to 90% B in 4 min, then isocratic elution at 90% for
5 min, subsequently the eluent B was decreased from 90% to 0%
in 1 min after which an equilibration of 10 min occurred. A flow
split of 9:1 was applied to the column effluent of which the
smaller fraction was sent to a Shimadzu SPD-M20A prominence
diode array detector and then to the mass spectrometer. The larger
fraction was directed to a FractioMate™ nanofractionator
(SPARK-Holland & VU, Emmen & Amsterdam, Netherlands)
controlled by FractioMator software (Spark-Holland, Emmen, The
Netherlands) or to a modified Gilson 235P robot allowing for
nanofractionation onto transparent 384-well plates (F-bottom,
rounded square well, polystyrene, without lid, clear, non-sterile;
Greiner Bio One, Alphen aan den Rijn, The Netherlands). The
nanofractionator was set to collect fractions continuously at a
resolution of 6 s/well. After fraction collection, the well plates
were dried overnight in a Christ Rotational Vacuum Concentrator
(RVC 2-33 CD plus, Zalm en Kipp, Breukelen, The Netherlands),
to remove any solvent remaining in the wells. The Vacuum
Concentrator was equipped with a cooling trap maintained at
80 C during operation. The dried plates were then stored at
20 C before bioassaying.
2.3. Plasma coagulation assay
The HTS coagulation assay was performed as described by Still
et al.47, following assay preparation and inhibitor pre-incubation
on the vacuum-centrifuge dried nanofractionated well plates. For
assay preparation, frozen plasma in 15 mL CentriStar™ tubes was
defrosted to room temperature in a warm water bath and then
centrifuged at 2000 rpm (805g) for 4 min in a 5810 R centrifuge
(Eppendorf, Germany) to remove possible particulate matter.
CaCl2 was dissolved in Milli-Q at room temperature to obtain a
20 mmol/L solution. For the pre-incubation step, the individual
inhibitor stock solutions were first diluted in PBS to the required
concentrations. Then, from each diluted inhibitor solution pre-
pared, 10 mL was pipetted to all wells of plate wells containing
freeze-dried nanofractionated venom fractions by a VWR Multi-
channel Electronic Pipet, followed by centrifuging the plate for
1 min at 2000 rpm (805g) in the same 5810 R centrifuge
(Eppendorf). Next, a pre-incubation step for 30 min at room
temperature was performed. Final concentrations of inhibitor
solutions used for the coagulation bioassay were 20, 4 andlecule toxin inhibitors on nanofractionated coagulopathic Crotalinae snake
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0.02%, 0.004% and 0.0008%, respectively). Venom-only analyses
were performed as control experiments, for which 10 mL PBS
instead of inhibitor solution was added to all wells of the vacuum-
centrifuge-dried nanofractionated well plates. For initiating the
coagulation assay, 20 mL of CaCl2 solution, followed by 20 mL
plasma, was pipetted onto all wells of the 384-well plates by a
Multidrop™ 384 Reagent Dispenser (Thermo Fisher Scientific,
Ermelo, The Netherlands) with rinsing of the Multidrop with
deionized water in between dispensing. Immediately after robot-
ically pipetting the CaCl2 and plasma solutions to a plate, a Var-
ioskan™ Flash Multimode Reader (Thermo Fisher Scientific) was
used to measure the absorbance of each well kinetically for
100 min at 595 nm at 25 C. Each nanofractionation analysis was
performed in at least duplicate. The slope value of each well was
normalized by dividing these slope values with the median value
from all wells in that single measurement, as described by Slag-
boom et al.48 and Xie et al.49. The coagulation chromatograms
were then plotted by using the normalized slope values (y-axis)
against the time of nanofraction collection (x-axis). For visual-
izing coagulation activity, the average rate of the kinetic coagu-
lation curve from 0 to 5 min was plotted for very fast coagulation
activity, from 0 to 20 min was plotted for slightly/medium
increased coagulation activity, and the single reading of the
coagulation curve at 100 min was plotted for anticoagulation ac-
tivity. Procoagulation was plotted in two different ways since all
significantly increased procoagulation curves reached their
maximum absorbance before 20 min and thus plotting the short
5 min kinetic time window allows discrimination of the most
potent acting procoagulation activities.
2.4. Correlation of biological data with MS and proteomics data
To identify the venom toxins that exhibited activity in the plasma
coagulation assay, we used the proteomics data and corresponding
accurate mass(es) described by Slagboom et al.48. For venoms
under study in this project that were not studied by Slagboom
et al.48, the same procedure as previously described48 was fol-
lowed to acquire and process proteomics data on these snake
venoms. The UniprotKB database was used to search for infor-
mation on class and possible known functions for the relevant
toxins. To import the proteomics data for the venoms included in
this study that were also included in the study of Slagboom
et al.48, the fingerprint profile LC‒UV traces (measured at 220,
254 and 280 nm) for the same venom analyses acquired in both
studies were used to align chromatograms with each other to
accommodate for potential slight differences in chromatographic
retention times. Consequently, the coagulopathic bioactivity peaks
together with UV data acquired for each nanofractionated venom
fraction obtained in this study could be linked to the MS-total ion
current (TIC) data, to the extracted ion current (XIC) data, and to
the protein IDs from the proteomics data acquired by Slagboom
et al.48. In order to construct XICs, an MS spectrum corresponding
to each bioactive peak found in the bioassay chromatogram was
first extracted from the MS data by averaging the spectra acquired
from the 50% and higher peak height range of each bioactive
peak. Then, XICs were plotted of the clearly observed m/z-values
and were then used to match these peak retention times with the
bioactivity peaks in the bioactivity chromatograms. The matched
exact masses were assigned to each corresponding bioactive peak
observed in the bioassay chromatogram by matching peak shape
and retention time. This way, the m/z-values found from the MSPlease cite this article as: Xie Chunfang et al., Neutralising effects of small mo
venoms, Acta Pharmaceutica Sinica B, https://doi.org/10.1016/j.apsb.2020.09data were correlated to each bioactive peak, and the accurate
monoisotopic masses were determined by applying the deconvo-
lution option in the MS software.3. Results
In this study, venoms from a variety of Crotalinae snake species
were nanofractionated by LC followed by low volume HTS
coagulation assaying to evaluate the inhibiting effects of vares-
pladib, marimastat and dimercaprol on separated venom toxins
that induce coagulopathic activities. The bioactive venom toxins
identified were assigned by correlating bioactivity chromatograms
to parallel obtained MS data and by using proteomics data ob-
tained for proteins present in wells showing coagulopathic activ-
ities. Using this approach, the neutralizing specificities of these
molecules on a variety of venom toxins were revealed. All ana-
lyses were performed at least in duplicate using venom concen-
trations of 1.0 mg/mL. Note that despite venom toxins being, in
general, rather stable during RPLC within the nanofractionation
analytics pipeline, some venom toxins might have (partly) dena-
tured and thereby lost their enzymatic activity; consequently, the
coagulation traces of venom-only analyses in control experiments
may vary slightly from each other.
3.1. The inhibitory effects of varespladib, marimastat and
dimercaprol on coagulopathic venom toxins from snake species of
the genus Bothrops
Two venoms from the most medically important genus of snakes
in Latin America were investigated in this study (B. asper, Costa
Rica and B. jararaca, Brazil). Envenomings by Bothrops spp. can
result in severe local tissue damage, pain and inflammation, as
well as systemic hemotoxicity characterised by haemorrhage and
coagulopathy50e52. The coagulopathic activity of the obtained
venom fractions from both species was assayed in the presence of
different concentrations of varespladib, marimastat and dimer-
caprol (Figs. 1 and 2). Duplicate bioassay chromatograms were
measured to assess repeatability and detailed descriptions of each
signal peak observed in the chromatograms are given in the
Supporting Information Section S1.
For B. asper venom, in the venom-only analysis (indicated as
“PBS” in the figures) revealed a sharp intense positive peak
(20.9 min) followed by a broad intense positive peak
(21.2e22.4 min) in both the very fast coagulation activity chro-
matograms and the slightly/medium increased coagulation activity
chromatograms. A broad negative peak (18.9e21.5 min) was also
observed in the anticoagulation activity chromatograms, demon-
strating that this venom exhibits both pro- and anticoagulant ac-
tivities. The broad peaks observed are likely the result of co-
eluting bioactive venom toxins. When testing the venom frac-
tions in the presence of small molecule toxin inhibitors, we found
that varespladib inhibited some of the observed anticoagulation
activities and reduced the potency of a number of the procoagulant
venom toxins. Contrastingly, marimastat and dimercaprol inhibi-
ted procoagulant venom effects to varying extents, but had little
inhibitory impact on anticoagulant toxins. For the very fast
coagulation activity, the first eluting sharp positive peak
(20.9 min) decreased in size with increasing concentrations of
both varespladib and marimastat. The intensity of the broad
intense positive peak (21.2e22.4 min) was also reduced sub-
stantially by varespladib and marimastat, and the tailing part waslecule toxin inhibitors on nanofractionated coagulopathic Crotalinae snake
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Figure 2 UV absorbance chromatograms and reconstructed
bioassay chromatograms of coagulopathic venom fractions of B.
jararaca in the presence of different concentrations of (A) varespla-
dib, (B) marimastat and (C) dimercaprol. The top superimposed
chromatograms are characteristic profiles of the UV trace detected at
220 254 and 280 nm. PBS indicates venom only samples where PBS
was used as a control for the inhibitors.
Figure 1 UV absorbance chromatograms and reconstructed
bioassay chromatograms of coagulopathic venom fractions of B. asper
in the presence of different concentrations of (A) varespladib, (B)
marimastat and (C) dimercaprol. The top superimposed chromato-
grams are characteristic profiles of the UV trace detected at 220, 254
and 280 nm. PBS indicates venom only samples where PBS was used
as a control for the inhibitors.
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Figure 3 UV absorbance chromatograms and reconstructed
bioassay chromatograms of coagulopathic venom fractions of C.
rhodostoma in the presence of different concentrations of (A) vares-
pladib, (B) marimastat and (C) dimercaprol. The top superimposed
chromatograms are characteristic profiles of the UV trace detected at
220, 254 and 280 nm. PBS indicates venom only samples where PBS
was used as a control for the inhibitors.
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stat. In contrast, both peaks (20.9 and 21.2e22.4 min) showed
limited change in the presence of dimercaprol. However, the
slightly/medium increased coagulation activity was almost fully
neutralised by 20 mmol/L dimercaprol. The front sharp positive
peak (20.9 min) was inhibited by all the three inhibitors in a
concentration-response manner, while the majority of the broad
intense positive peak (21.2e22.4 min) was inhibited by 20 mmol/L
varespladib, but only the tailing part of this peak was inhibited by
20 mmol/L marimastat. For anticoagulant venom activity, the front
part of the broad negative peak (21.2e22.4 min) was fully neu-
tralised by a concentration as low as 0.8 mmol/L varespladib,
while the remaining part was not inhibited at all by this molecule.
Surprisingly, the broad negative peak was split into two individual
peaks (18.9e20.0 and 20.1e21.0 min) by 0.8 mmol/L marimastat,
but both peaks remained unchanged in the presence of increasing
concentrations of concentration. No inhibition of anticoagulation
activity was observed for dimercaprol.
Next, B. jararaca venom was fractionated and the fractions
assessed in the presence of varespladib, marimastat and dimer-
caprol, as outlined above for B. asper. The resulting bioassay
chromatograms of B. jararaca analyses are shown in Fig. 2. A
positive peak with a co-eluting shoulder peak (20.2e21.7 min)
was observed in both the very fast coagulation chromatogram and
the slightly/medium increased coagulation chromatogram in the
venom-only analysis. This peak decreased in a relatively compa-
rable manner with increasing concentrations of varespladib,
marimastat and dimercaprol, although full inhibition was not
achieved at the highest concentration of any of the inhibitors
tested (20 mmol/L). Contrasting strongly with its congener B.
asper, only a very weak negative peak (20.5e21.1 min) was
detected, demonstrating limited anticoagulant venom activity; this
peak was not inhibited by varespladib, marimastat or dimercaprol
at any of the concentrations tested.
3.2. The inhibitory effects of varespladib, marimastat and
dimercaprol on coagulopathic venom toxins from C. rhodostoma
and D. acutus
Next, we assessed the inhibitory capability of the same small
molecule toxin inhibitors on two monotypic medically important
Crotalinae snake species, namely C. rhodostoma from Southeast
Asia53, and D. acutus from southern China and northern Viet-
nam54. Venoms from both species are abundant in hemotoxic
compounds that can deregulate blood coagulation and cause se-
vere coagulopathy in snakebite victims55,56. In this study, their
venoms were fractionated and the coagulopathic activity of the
obtained fractions was assessed in the presence of varespladib,
marimastat and dimercaprol. The resulting bioassay chromato-
grams are shown in Figs. 3 and 4. The duplicate bioassay chro-
matograms of the C. rhodostoma and D. acutus venom analyses,
including detailed descriptions of each bioactivity peak, are pro-
vided in the Supporting Information Section S2.
The bioactivity chromatogram of C. rhodostoma venom
(Fig. 3) showed two sharp positive peaks (19.7 and 20.4 min) for
the very fast coagulation activity as well as for the slightly/me-
dium increased coagulation activity, while a moderate negative
peak (19.9 min) was observed for the anticoagulation activity.
Both procoagulation activities were gradually reduced byPlease cite this article as: Xie Chunfang et al., Neutralising effects of small molecule toxin inhibitors on nanofractionated coagulopathic Crotalinae snake
venoms, Acta Pharmaceutica Sinica B, https://doi.org/10.1016/j.apsb.2020.09.005
Figure 4 UV absorbance chromatograms and reconstructed
bioassay chromatograms of coagulopathic venom fractions of D.
acutus venom in the presence of different concentrations of (A) var-
espladib, (B) marimastat and (C) dimercaprol. The top superimposed
chromatograms are characteristic profiles of the UV trace detected at
220, 254 and 280 nm. PBS indicates venom only samples where PBS
was used as a control for the inhibitors.
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procoagulation activities, however, were not fully neutralised by
the highest varespladib or marimastat concentrations tested
(20 mmol/L), suggesting perhaps a non-specific inhibitory effect.
In contrast to these findings, we observed very limited inhibition
of both procoagulant peaks with dimercaprol. The negative anti-
coagulation peak (19.9 min) observed was not inhibited by any of
the inhibitory molecules tested.
The bioassay chromatograms constructed from the measure-
ment of LC nanofractions of D. acutus venom in the presence of
the different concentrations of varespladib, marimastat and
dimercaprol are shown in Fig. 4. In the venom-only analysis, a co-
eluting intense positive peak (21.0e22.2 min) was followed by a
very weak positive peak (22.7e23.2 min) in the very fast coag-
ulation activity chromatogram. The later eluting weak positive
peak (22.7e23.2 min) was fully neutralised by both varespladib
and marimastat at a 4 mmol/L concentration. The broad intense
positive peak (21.0e22.2 min) was substantially reduced by var-
espladib in a concentration-dependent fashion, but was only
slightly inhibited by the highest marimastat concentration tested
(20 mmol/L). In the slightly/medium increased coagulation activ-
ity chromatogram, several positive peaks eluted close together
(21.2e23.4 min) and were observed as non-baseline separated
peaks in the venom-only analysis. They were all reduced by
increasing varespladib concentrations and the tailing part of the
broad peak was fully neutralised at 20 mmol/L varespladib. Mar-
imastat had a limited effect on these peaks, with only the tailing
part of the peaks partly neutralised at the highest concentration
tested (20 mmol/L). For both the very fast coagulation activity and
the slightly/medium increased coagulation activity, dimercaprol
showed no inhibitory effect at 0.8 mmol/L, though showed mod-
erate inhibition at 4 and 20 mmol/L. For anticoagulant venom
activity, a sharp intense negative peak (20.7 min), followed by a
very weak negative peak (21.5 min), was observed in the venom-
only analysis. The intense negative peak (20.7 min) was reduced
in a dose dependent manner by varespladib, with complete inhi-
bition achieved at the 4 mmol/L concentration, whereas the weak
negative peak (21.5 min) was not affected by varespladib. Neither
of these anticoagulation activity peaks was affected by marimastat
and dimercaprol.
3.3. Identification of coagulopathic venom toxins neutralised by
the small molecule inhibitors varespladib, marimastat and
dimercaprol
The venom toxins responsible for the coagulation activities
observed for each of the four snake venoms were tentatively
identified by correlating the acquired data with MS and prote-
omics data previously obtained by Slagboom et al.48 (Table 1).
Bioactivities were linked to accurate molecular masses and
tentative protein identities by aligning the characteristic LC‒UV
chromatograms obtained for each venom. For those toxins where
no exact mass data was acquired by LC‒MS, only the proteomics
data obtained from the Mascot searches is provided.
By comparing Table 1 with Figs. 1‒4, the inhibiting effects of
varespladib, marimastat and dimercaprol on individual Crotalinae
venom toxins were assessed. Most anticoagulant toxins identified
were PLA2s. The PLA2s in B. asper venom were partly neutralised
by 20 mmol/L varespladib, and in D. acutus venom were fullylecule toxin inhibitors on nanofractionated coagulopathic Crotalinae snake
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Table 1 Correlated MS and proteomics data matching coagulopathic venom toxins.
Species Peak retention
time (min)
Peak activity Mascot results
matching the
exact mass
Exact mass
from MS data
Exact mass
calculated from
Mascot data
Toxin class Dose required for full
inhibition
B. asper 18.9e20.0 Anticoagulation PA2H2_BOTAS 13,714.565 13,715 PLA2 PN
20.1e21.0 Anticoagulation PA2HA_BOTAS 13,912.465 13,897 PLA2 PN
20.1e21.0 Anticoagulation PA2H3_BOTAS 13,765.581 13,766 PLA2 PN
21.0e21.5 Anticoagulation PA2B3_BOTAS 13,957.533 13,957 PLA2 PN
21.0e21.5 Anticoagulation PA2A2_BOTAS e 14,194 PLA2 PN
21.0e21.5 Anticoagulation VM2_BOTAS e 53,564 SVMP NOI
20.8e22.4 Procoagulation VSPL_BOTAS e 28,019 SVSP PN
20.8e22.4 Procoagulation VM1B1_BOTAS e 45,936 SVMP PN
21.2e22.4 Procoagulation SLA_BOTAS 7084 CTL PN
B. jararaca 20.5e21.1 Anticoagulation e e e e NOI
20.2e21.7 Procoagulation VSPA_BOTJA e 25,584 SVSP PN
20.2e21.7 Procoagulation VSP1_BOTJA e 25,742 SVSP PN
20.2e21.7 Procoagulation VSP2_BOTJA e 27,894 SVSP PN
20.2e21.7 Procoagulation VSP12_BOTJA e 27,988 SVSP PN
20.2e21.7 Procoagulation VSP14_BOTJA e 27,843 SVSP PN
20.2e21.7 Procoagulation VSP20_BOTJA e 27,815 SVSP PN
C. rhodostoma 19.3e20.5 Anticoagulation PA2BD_CALRH 13,665.085 13,665 PLA2 NOI
19.3e20.5 Anticoagulation PA2AB_CALRH e 14,352 PLA2 NOI
19.3e20.5 Anticoagulation VSPF1_CALRH e 26,570 SVSP NOI
19.3e20.5 Anticoagulation SLEA_CALRH e 15,962 CTL NOI
19.3e20.5 Anticoagulation SLEB_CALRH e 15,190 CTL NOI
19.3e21.6 Procoagulation VSPF2_CALRH e 29,145 SVSP PN
19.9e21.6 Procoagulation SLYA_CALRH e 15,796 CTL PN
19.9e21.6 Procoagulation SLYB_CALRH e 16,770 CTL PN
D. acutus 20.4e20.9 Anticoagulation PA2A_DEIAC e 14,820 PLA2 4 mmol/L varespladib
20.4e20.9 Anticoagulation SL_DEIAC e 18,332 CTL 4 mmol/L varespladib
21.4e21.7 Anticoagulation e e e e NOI
21.0e22.7 Procoagulation VSP1_DEIAC e 29,480 SVSP PN
21.0e22.7 Procoagulation VSPA_DEIAC e 26,132 SVSP PN
21.4e22.7 Procoagulation SLCB_DEIAC e 17,133 CTL PN
21.4e22.7 Procoagulation VM1AC_DEIAC e 47,690 SVMP PN
21.4e22.7 Procoagulation VM11_DEIAC e 47,845 SVMP PN
21.4e22.7 Procoagulation VM1H5_DEIAC e 46,518 SVMP PN
21.4e22.7 Procoagulation VM3AK_DEIAC e 69,752 SVMP PN
22.7e23.4 Procoagulation VM3A2_DEIAC e 27,151 SVMP 20 mmol/L varespladib/4 mmol/
L marimastat
22.7e23.4 Procoagulation VM3AH_DEIAC e 70,721 SVMP 20 mmol/L varespladib/4 mmol/
L marimastat
Peak retention times are adapted from Figs. 1‒4; PLA2 Z phospholipase A2; SVMP Z snake venom metalloproteinase; SVSP Z snake venom
serine protease; CTLZC-type lectin; PN Z partly neutralised at 20 mmol/L inhibitor concentrations; NOI Z no observed inhibition; ‒ Z not
applicable.
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no anticoagulant toxin was identified from the Mascot results for
B. jararaca venom, and no inhibition was observed on the anti-
coagulation peaks from C. rhodostoma venom by varespladib,
marimastat and dimercaprol. The tentatively identified procoagu-
lant toxins were mainly SVMPs, SVSPs and C-type lectins (CTL).
Only two SVMPs in D. acutus venom identified as procoagulant
toxins were fully inhibited by 4 mmol/L marimastat, and by
20 mmol/L varespladib. The potential inhibition of SVMPs by
varespladib can indicate that varespladib may not exert its effect
solely by inhibition of the phospholipid hydrolysing activity of
PLA2s, though further research is required to robustly test this
hypothesis. Critically, as several venom toxins were found to co-
elute in regions where bioactives were observed, the unambiguous
identification of the individual contribution of each toxin to each
coagulation bioactivity peak, and their relative contributions toPlease cite this article as: Xie Chunfang et al., Neutralising effects of small mo
venoms, Acta Pharmaceutica Sinica B, https://doi.org/10.1016/j.apsb.2020.09coagulotoxicity, are difficult to interpret. Additionally, some non-
polar (late eluting) venom toxins might (partially) denature during
LC separation and become biologically inactive and as such may
not be detected by the coagulopathic bioassay. A detailed
description of the results discussed here is provided in the
Supporting Information Section S3.
4. Discussion
Snake envenoming by pit vipers is usually characterized by coa-
gulopathy, haemorrhage and local effects, such as swelling and
tissue damage around the site of the bite1. Our study investigated
the neutralizing capabilities of promising small molecule-based
drug candidates on the coagulopathic activities of pit viper
venoms by using nanofractionation analytics. All venoms showed
both procoagulation activities and anticoagulation activities, albeitlecule toxin inhibitors on nanofractionated coagulopathic Crotalinae snake
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venom. Our findings reveal that the PLA2 inhibitor varespladib
inhibited many of the observed anticoagulation activities, and
surprisingly also exhibited varying inhibitory effects on several of
the observed procoagulation activities. However, future work is
required to unravel the mechanisms of this inhibition of procoa-
gulant activity, given that such toxins are unlikely to be PLA2s.
We cannot rule out that non-specific effects at high inhibitor
concentrations are responsible for these observations. Snake
venom PLA2s hydrolyse phospholipids to release fatty acids and
lysophospholipids, resulting in damage to cell membranes, or
prolong/delay prothrombin time to prevent blood clotting. These
toxins, often acting synergistic with other venom toxin families
such as SVMPs and SVSPs57,58, contribute to various toxicities
observed following snake envenoming, including hemotoxic,
myotoxic and neurotoxic effects, and thus are one of the main
players in resulting morbidity and mortality48,59,60. By using
varespladib, the enzymatic toxicities mediated by PLA2s can be
alleviated, delayed and/or abrogated14,22,24,61. However, additional
work is required to fully understand the inhibitory potential of
varespladib for snakebite. For example, Wang et al.13 previously
demonstrated that varespladib was capable of fully inhibiting the
haemorrhagic toxicity induced by D. acutus venom when it was
administered subcutaneously or intramuscularly to mice, whilst
also having some inhibitory effect of the myotoxic activities
caused by this venom. Despite these findings, our results show that
not all coagulopathic toxins found in D. acutus venom were
inhibited by varespladib, and indeed similar observations were
observed with the other venoms under study. Thus, while vares-
pladib undoubtedly remains a highly promising snakebite thera-
peutic, more work is required to fully understand its toxin-
neutralising specificity.
The SVMP inhibitors marimastat and dimercaprol only partly
inhibited the procoagulation activities revealed in this study, and
showed little inhibitory activity against anticoagulant toxins
(mostly identified as PLA2s). These findings are in line with the
anticipated specificity of their mechanism of action, which interact
via different mechanisms on the active sites of SVMPs16,17,37.
Despite previous studies showing that marimastat and dimercaprol
inhibited SVMP activity from the venoms of Crotalus atrox and
Echis spp.16,17,37, here we found that marimastat and dimercaprol
showed only a degree of inhibition against certain procoagulant
toxins present in the venoms of the pit vipers under study. How-
ever, these findings can be rationalised, given that many of the
procoagulant toxins tentatively identified here were not SVMPs
(Table 1). Interestingly, neither marimastat nor dimercaprol had a
noticeable inhibitory effect on the coagulotoxicity of C. rhodos-
toma venom, and indeed no SVMP toxins were identified among
the bioactives detected in this study. Thus, specific inhibitors
against C-type lectins and/or SVSP toxins may be required to
prevent procoagulant venom effects caused by this species. It is
worth noting that Albulescu et al.37 recently demonstrated that the
serine protease inhibitor nafamostat was capable of broadly neu-
tralised the SVSP activity of a variety of viper venoms (including
B. asper) in a dose-dependent manner, and thus use of this mol-
ecules seems likely to be a logical starting point for future inhi-
bition studies using C. rhodostoma venom.
It is worth highlighting that these inhibitor-based therapeutic
candidates have different specificities and act on different toxin
classes found in snake venoms. Therefore, in the long term, uti-
lising combinations of such molecules (e.g., the PLA2 inhibitor
varespladib, SVMP inhibitor marimastat and/or chelatorPlease cite this article as: Xie Chunfang et al., Neutralising effects of small mo
venoms, Acta Pharmaceutica Sinica B, https://doi.org/10.1016/j.apsb.2020.09dimercaprol, together with serine protease inhibitors and other
venom toxin inhibitors) seems likely to be a potentially viable
strategy for the development of adjunct and/or stand-alone treat-
ments of snakebite, that may be of great value for use as early
interventions in remote rural areas where treatment delays
contribute to poor patient outcomes. In the recent study of
Albulescu et al.37, we demonstrated that a therapeutic combination
of varespladib and marimastat protected experimental animals
from the lethal effects of a variety of viper venoms, including that
of B. asper studied here. A combination of various different in-
hibitors (or indeed modalities, e.g., small molecules and mono-
clonal antibodies or nanobodies) may prove to be the only viable
approach to obtain affordable broad-spectrum therapeutics for
treating snakebite globally9,22,26. However, considerable further
work is required to robustly explore this view, ideally via the
application of both in vitro and in vivo studies, using both a di-
versity of chemical entities as potential inhibitory agents and a
variety of snake venoms that represent full (global) toxin diversity.
In the longer term, such in vivo studies should also explore
appropriate dosing schedules and administration routes of identi-
fied lead candidates to robustly predict their translational potential
for use in human clinical trials. Our findings here reinforce the
notion that small molecule based toxin inhibitors are viable en-
tities as next-generation snakebite therapeutics, and though hur-
dles associated with overcoming variable venom compositions and
distinct toxin inhibiting specificities remain, there is a strong
rationale for future research programmes to continue to evaluate
these molecules as valuable repurposing candidates for snakebite.5. Conclusions
The coagulation activities of toxins isolated from the venoms of
the Crotalinae snakes B. asper, B. jararaca, C. rhodostoma and D.
acutus were investigated by the application of a recently devel-
oped HTS coagulation assay after venom nanofractionation by
LC. The inhibitory potential of the small molecule toxin inhibitors
varespladib, marimastat and dimercaprol against the bioactivities
of nanofractionated pit viper venom toxins was then evaluated. All
inhibitors under study are either registered drugs or at least phase
II approved candidates known to inhibit PLA2 or protease activity.
This implies that these compounds are clinically safe and as such
will this significantly increase the chances of these compounds to
be developed into eventual snakebite treatments as compared to
studying non-clinically tested compounds. Coagulopathic venom
toxins were tentatively identified by correlating bioassay activity
chromatograms to MS and proteomics data obtained in parallel.
Our results showed that the three repurposed drug candidates
exhibited varying inhibitory effects against distinct pro- and
anticoagulant venom toxins identified in each venom. We
conclude that combinations of small molecule drugs capable of
inhibiting distinct toxin families may be required to ensure broad
neutralization of a diversity of snake venoms.
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